(1) Initial treatment of CHB patients
The 2015 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B recommends Tenofovir as one of the first choices for patients with CHB who are eligible for antiviral therapy. Tenofovir antiviral therapy should strictly meet the indications. For those who have not obtained virological response for Tenofovir monotherapy for ≥48 weeks, the patient's compliance should be evaluated. According to the comprehensive evaluation of the patient's liver basic disease, the dynamic decline of HBV DNA during treatment, and the ALT recurrence, continue to take a single drug as appropriate. Treatment or addition of FTC, LAM, LdT or ETV for optimal treatment.
(2) CHB patients treated by CHB
➤Lamivudine (LAM) treatment: can be used for Tenofovir antiviral therapy;
➤Telbivudine (LdT) treatment: can be used for Tenofovir antiviral therapy;
➤entecavir (ETV) treatment: can be used for Tenofovir antiviral therapy;
➤Adefovir dipivoxil (ADV) treatment: ADV treatment and good response patients can switch to Tenofovir treatment as appropriate; but ADV treatment failure patients need to be careful to switch to Tenofovir treatment, consider Tenofovir + ETV / LAM / LdT antiviral treatment.
(3) patients with decompensated cirrhosis
Tenofovir can be used as a first-line treatment for patients with decompensated hepatitis B cirrhosis who are eligible for antiviral indications.
(4) Patients with HBV-related liver failure
Patients with hepatitis B liver failure may be considered for antiviral therapy with Tenofovir to inhibit HBV replication and improve patient outcomes.
(5) HBV-related liver cancer patients
For patients with HCC detectable in HBV DNA, Tenofovir is one of the first-line antiviral drugs.